CA2630848C - Use of 3-iodo-l-phenylalanine or 4-iodo-l-phenylalanine in the treatment of malignant neoplasia - Google Patents

Use of 3-iodo-l-phenylalanine or 4-iodo-l-phenylalanine in the treatment of malignant neoplasia Download PDF

Info

Publication number
CA2630848C
CA2630848C CA2630848A CA2630848A CA2630848C CA 2630848 C CA2630848 C CA 2630848C CA 2630848 A CA2630848 A CA 2630848A CA 2630848 A CA2630848 A CA 2630848A CA 2630848 C CA2630848 C CA 2630848C
Authority
CA
Canada
Prior art keywords
phenylalanine
iodo
therapy
use according
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2630848A
Other languages
English (en)
French (fr)
Other versions
CA2630848A1 (en
Inventor
Samuel Samnick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2630848A1 publication Critical patent/CA2630848A1/en
Application granted granted Critical
Publication of CA2630848C publication Critical patent/CA2630848C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Soft Magnetic Materials (AREA)
CA2630848A 2005-11-25 2006-11-27 Use of 3-iodo-l-phenylalanine or 4-iodo-l-phenylalanine in the treatment of malignant neoplasia Active CA2630848C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05025776 2005-11-25
EP05025776.5 2005-11-25
PCT/EP2006/011367 WO2007060011A1 (en) 2005-11-25 2006-11-27 Therapy of malignant neoplasias

Publications (2)

Publication Number Publication Date
CA2630848A1 CA2630848A1 (en) 2007-05-31
CA2630848C true CA2630848C (en) 2014-10-07

Family

ID=37744207

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2630848A Active CA2630848C (en) 2005-11-25 2006-11-27 Use of 3-iodo-l-phenylalanine or 4-iodo-l-phenylalanine in the treatment of malignant neoplasia

Country Status (15)

Country Link
US (1) US8268888B2 (https=)
EP (1) EP1962822B1 (https=)
JP (1) JP5108781B2 (https=)
KR (1) KR20080074193A (https=)
AT (1) ATE454144T1 (https=)
AU (1) AU2006316781B2 (https=)
CA (1) CA2630848C (https=)
DE (1) DE602006011650D1 (https=)
DK (1) DK1962822T3 (https=)
ES (1) ES2341575T3 (https=)
IL (1) IL191690A (https=)
NZ (1) NZ568367A (https=)
PL (1) PL1962822T3 (https=)
PT (1) PT1962822E (https=)
WO (1) WO2007060011A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2948154C (en) 2014-05-07 2017-09-26 The University Of Akron Radioopaque, iodine functionalized phenylalanine-based poly(ester urea)s
WO2025202716A1 (en) * 2024-03-26 2025-10-02 Telix Pharmaceuticals (Innovations) Pty Ltd Combination therapy for treating glioblastomas

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5816999A (en) * 1997-07-24 1998-10-06 Bischoff; Jeffrey Flexible catheter for the delivery of ionizing radiation to the interior of a living body
AU1932900A (en) * 1998-12-04 2000-06-26 Medivas, Llc Methods for detection of vulnerable plaques using a detectable lipid-avid agent
WO2004050168A2 (en) * 2002-11-27 2004-06-17 Board Of Regents, The University Of Texas System Radiopharmaceuticals and radioactive microspheres for locoregional ablation of abnormal tissues

Also Published As

Publication number Publication date
KR20080074193A (ko) 2008-08-12
US8268888B2 (en) 2012-09-18
DK1962822T3 (da) 2010-05-17
EP1962822B1 (en) 2010-01-06
JP5108781B2 (ja) 2012-12-26
ES2341575T3 (es) 2010-06-22
DE602006011650D1 (de) 2010-02-25
PL1962822T3 (pl) 2010-07-30
AU2006316781A1 (en) 2007-05-31
WO2007060011A1 (en) 2007-05-31
AU2006316781B2 (en) 2012-06-14
JP2009517356A (ja) 2009-04-30
US20100003268A1 (en) 2010-01-07
ATE454144T1 (de) 2010-01-15
PT1962822E (pt) 2010-04-09
IL191690A0 (en) 2009-08-03
NZ568367A (en) 2010-11-26
IL191690A (en) 2011-10-31
EP1962822A1 (en) 2008-09-03
CA2630848A1 (en) 2007-05-31

Similar Documents

Publication Publication Date Title
JP7839135B2 (ja) 免疫療法に対する抗腫瘍免疫応答を促進するための標的化放射線療法（ｔｒｔ）の使用
JP6590985B2 (ja) 抗原発現を上方制御するための方法
O'Donnell et al. Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium‐DOTA‐peptide‐ChL6
Aft et al. Enhancing targeted radiotherapy by copper (II) diacetyl-bis (N 4-methylthiosemicarbazone) using 2-deoxy-D-glucose
HK1256497A1 (en) Combination therapy comprising anti-cd20 antibody and the radiolabeled hh1 monoclonal antibody
US20170348441A1 (en) Therapy of malignant neoplasias
CN121130116A (zh) 治疗癌症的方法
CA2630848C (en) Use of 3-iodo-l-phenylalanine or 4-iodo-l-phenylalanine in the treatment of malignant neoplasia
O'Donnell et al. Combined modality radioimmunotherapy with Taxol and 90Y-Lym-1 for Raji lymphoma xenografts
US20110300067A1 (en) Methods for increasing efficacy of radioimmunotherapy of melanoma
Rathmann Development of a Versatile Platform for Combination Targeted Radionuclide and Immune Cell Recruitment Therapies Using Bio-Orthogonal Chemistry
WO2007060012A2 (en) Use of l-phenylalanine conjugated to an emitting isotope for therapy of hormone dependent carcinoma
JP2024539952A (ja) 放射性核種錯体の組み合わせ療法
JP2016210688A (ja) 放射性抗腫瘍剤、及び、抗腫瘍用キット

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 18TH ANNIV.) - STANDARD

Year of fee payment: 18

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241122

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241122

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241122

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 19TH ANNIV.) - STANDARD

Year of fee payment: 19

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251104

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251104